EP2390661A1 - An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell - Google Patents
An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell Download PDFInfo
- Publication number
- EP2390661A1 EP2390661A1 EP20100004611 EP10004611A EP2390661A1 EP 2390661 A1 EP2390661 A1 EP 2390661A1 EP 20100004611 EP20100004611 EP 20100004611 EP 10004611 A EP10004611 A EP 10004611A EP 2390661 A1 EP2390661 A1 EP 2390661A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- anchoring
- product
- cho cell
- capturing means
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004978 chinese hamster ovary cell Anatomy 0.000 title claims abstract description 70
- 238000004873 anchoring Methods 0.000 title claims abstract description 58
- 239000000427 antigen Substances 0.000 claims abstract description 43
- 102000036639 antigens Human genes 0.000 claims abstract description 43
- 108091007433 antigens Proteins 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000012634 fragment Substances 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims description 144
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 11
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 8
- 239000006249 magnetic particle Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 56
- 239000000872 buffer Substances 0.000 description 29
- 238000000926 separation method Methods 0.000 description 21
- 230000028327 secretion Effects 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000007885 magnetic separation Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000011325 microbead Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000007898 magnetic cell sorting Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 3
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011553 magnetic fluid Substances 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940079023 tysabri Drugs 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- ZBQCCTCQUCOXBO-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine Chemical compound CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 ZBQCCTCQUCOXBO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
Definitions
- the invention pertains to an anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, as well as to uses thereof.
- the invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention pertains to an anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, as well as to uses thereof.
- the affinity matrix technology was established by Manz and coworkers (1995) to study the secretion of antibodies by hybridomas and cytokine secretion of activated T lymphocytes.
- To create an artificial affinity matrix on the cell surface primary amine residues of surface molecules were biotinylated.
- cells were labeled directly with an avidinated catch antibody, specific for the secreted molecule.
- cells were allowed to secrete in gelatine, a medium with decreased permeability to reduce diffusion of the secreted molecule.
- the catch antibody could then capture the secreted molecules in the vicinity of the cell surface.
- Secreting cells were subsequently labelled with fluorescent reagents, specific for the secreted molecule, to allow flow cytometric analysis and cell sorting. Borth et al.
- CHO cells provide glycosylation patterns of the synthesized proteins that are similar to those provided in human cells. Therefore, such proteins are particularly suitable as therapeutic proteins.
- the present invention provides methods for detecting, analyzing and separating antigen-stimulated T cells on the basis of secreted product, where the product is secreted.
- the methods are based on capture and relocation to the cell surface of the secreted product.
- the captured product permits the cell to be detected, analyzed and, if desired, sorted, according to the presence, absence or amount of the product present.
- the means of capture comprises a product-specific anchoring/capturing means.
- the invention provides, in a first aspect , an anchoring/capturing means for selecting or analyzing a CHO cell according to a product that is being synthesized and secreted by the CHO cell into a medium surrounding the cell.
- this anchoring/capturing means comprises
- selecting may comprise also enriching and isolating.
- substantially enriched indicates that a cell population is at least about 50-fold, more preferably at least about 500-fold, and even more preferably at least about 5000-fold or more enriched from an original mixed cell population comprising the desired cell population.
- the present invention provides methods for obtaining a cell population enriched in CHO cells which secrete a product.
- the anchoring/capturing means may comprise a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antigen-binding fragment for binding the secreted product
- the anchoring/capturing means can be, in one embodiment of the invention, a bispecific antibody.
- bispecific antibody and bispecific antibodies also known as bifunctional antibodies, intends antibodies that recognize two different antigens by virtue of possessing at least one first antigen combining site specific for a first antigen or hapten, and at least one second antigen combining site specific for a second antigen or hapten.
- Such antibodies can be produced by recombinant DNA methods or include, but are not limited to, antibodies chemically by methods known in the art.
- this anchoring/capturing means is a conjugate of at least two antibodies or antigen-binding fragments that were chemically joined, preferably at the Fc moiety.
- Methods for conjugating are known to a person of skill in the art.
- the first antibody or the first antigen-binding fragment of the anchoring/capturing means binds specifically to a surface molecule of the CHO cell, thereby anchoring the anchoring/capturing means to the CHO cell.
- the second antibody or a second antigen-binding fragment In order for the second antibody or a second antigen-binding fragment to be able to binding the product from the CHO cell, the first antibody or antigen-binding fragment must be oriented such to the second antibody or antigen-binding fragment that binding of the product is not sterically hindered.
- the first antibody or the first antigen-binding fragment for anchoring the anchoring/capturing means to the extracellular surface of the CHO cell is a monoclonal antibody or an antigen-binding fragment thereof, in particular the monoclonal antibody HA3-21F5.6 or an antigen-binding fragment thereof.
- the first antibody is the monoclonal antibody HA3-21F5.6 that is being secreted by the hybridoma cell line that was deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany, on April 30, 2010. The generation of this first antibody is described in the examples.
- the first antibody recognizes in a preferred embodiment a target on the extracellular surface of the CHO cell that is constitutively expressed. In another embodiment, the first antibody recognizes a target on the extracellular surface of the CHO cell that is expressed upon induction of the cell with a chemical inducer.
- the second antibody or the second antigen-binding fragment of the anchoring/capturing means is, in a preferred embodiment, specifically binding a CD303 (BDCA-2) antibody as the product.
- CD303 (BDCA-2) is a Ca 2+ -dependent type II C-type lectin that is specifically expressed by human plasmacytoid dendritic cells (Rock et al., 2007).
- the invention provides the use of an anchoring/capturing means as described above and herein for selecting or analyzing a CHO cell according to a product secreted by the CHO cell.
- the invention provides CHO cell bound to an anchoring/capturing means as described above and herein.
- the invention provides a method for selecting or analyzing a CHO cell according to a product secreted by the CHO cell.
- the method comprises the following steps:
- the present invention does not depend on a chemical modification of molecules on the surface of the CHO cell. Moreover, no streptavidin, avidin or alike need be used for direct treatment of the CHO cell.
- the cells that have a secreted product bound to the second antibody or the second antigen-binding fragment of the anchoring/capturing means are not lysed as part of the selection or analysis but remain intact.
- the product that is being secreted from the CHO cell is preferably is a protein, in particular an antibody or an antigen-binding fragment of an antibody.
- the antigen-binding fragment can be chosen from the group consisting of whole antibodies, bispecific antibodies, chimeric antibodies, Fab, F (ab')2, single chain V region fragments (scFv), fusion proteins, aptomers, carbohydrates, and lectins.
- a preferred secreted antibody is an antibody against the molecule CD303 (BDCA-2), which is known in the art.
- the secreted product is an antibody, then it is preferably chosen from the group consisting of humanized antibodies, chimeric antibodies, human antibodies, and antigen-binding fragments thereof.
- the cell After binding of the product to the CHO cell via the anchoring/capturing means, the cell may be detectably labeled, e.g. using a third or forth antibody, each antibody carrying a detectable label (the same or different labels). By using different antibodies, a stronger signal for detection may be generated.
- the detectable label may comprise at least one from the group consisting of magnetic particles, fluorophores, radioactive isotopes, haptenes, and chromophores.
- the labeled cells can then be separated using standard cell sorting techniques based on these labels. Such techniques include, but are not limited to, flow cytometry, FACS, high gradient magnetic separation, centrifugation.
- magnetic cell sorting MMS can be used to identify CHO cells excreting the product or excreting the product at certain levels. Thereby, CHO cell lines with certain secretion characteristics can be obtained, such as highly excreting CHO cell lines.
- Preferred magnetic labeling methods include colloidal superparamagnetic particles in a size range of 5 to 200 nm, preferably in a size of 10 to 100 nm. These magnetic particles allow a quantitative magnetic labeling of cells, thus the amount of coupled magnetic label is proportional to the amount of bound product, and the magnetic separation methods are sensitive to different amounts of product secretion.
- Colloidal particles with various specificities are known in the art, and are available, for example, through Miltenyi Biotec GmbH.
- the use of immunospecific fluorescent or magnetic liposomes can also be used for quantitative labeling of captured product.
- the liposomes contain magnetic material and/or fluorescent dyes conjugated with antibody on their surfaces, and magnetic separation is used to allow optimal separation between nonproducing, low producing, and high producing cells.
- the magnetic separation can be accomplished with high efficiency by combining a second force to the attractive magnetic force, causing a separation based upon the different strengths of the two opposed forces.
- Typical opposed forces are, for example, forces induced by magnetic fluids mixed in the separation medium in the magnetic separation chamber, gravity, and viscous forces induced by flow speed of medium relative to the cell.
- Any magnetic separation method preferably magnetic separation methods allowing quantitative separation will be used. It is also contemplated that different separation methods can be combined, for example, magnetic cell sorting can be combined with FACS, to increase the separation quality or to allow sorting by multiple parameters.
- HGMS high gradient magnetic separation
- the product is labeled by attaching it to a magnetic particle.
- the attachment is generally through association of the product with a label moiety which is conjugated to a coating on the magnetic particle which provides a functional group for the conjugation.
- the captured product thus coupled to a magnetic "label”, is suspended in a fluid, which is then applied to the chamber.
- the magnetically labeled target cell is retained in the chamber; if the chamber contains a matrix, it becomes associated with the matrix. Cells which do not have or have only a low amount of magnetic labels pass through the chamber.
- the retained cells can then be eluted by changing the strength of, or by eliminating, the magnetic field or by introducing a magnetic fluid.
- the selectivity for a captured product is supplied by the label moiety conjugated either directly or indirectly to the magnetic particle or by using a primary antibody and a magnetic particle recognizing the primary antibody.
- the chamber across which the magnetic field is applied is often provided with a matrix of a material of suitable magnetic susceptibility to induce a high magnetic field gradient locally in the camber in volumes close to the surface of the matrix. This permits the retention of fairly weakly magnetized particles.
- Publications describing a variety of HGMS systems are known in the art, and include, for example, U. S. Patent No. 4,452,773 , U. S. Patent No.
- These conditions are known to those of skill in the art and include, inter alia, appropriate temperature, pH, and concentrations of salts, growth factors and substrates in the incubation medium, as well as the appropriate concentrations of gas in the gaseous phase.
- the time of incubation is such that product secretion by the cells is still in a linear phase.
- the appropriate conditions can be determined empirically and such a determination is within the skill of one in the art.
- cell secretion can be modified, that is, upregulated, induced, or reduced using a biological modifier.
- the biological modifiers can be added at any time but are preferably added to the incubation medium. Alternatively, the cells can be pretreated with these agents or cells prior to the incubation step. Suitable biological modifiers include, but are not limited to, molecules and other cells.
- Suitable molecules include, but are not limited to, drugs, cytokines, small molecules, hormones, combinations of interleukins, lectins and other stimulating agents, e.g., PMA, LPS, bispecific antibodies and other agents that modify cellular functions or protein expression.
- the culturing conditions are also such that product is essentially not captured or is captured to a much lesser extent by another cell, so as to distinguish non-producing cells from product producing cells, or high producers from low producers.
- the incubation time is between five minutes and ten hours, and is more usually between one and five hours.
- the incubation medium can optionally include a substance that slows diffusion of the product from the producer cell.
- the CHO cell is cultured in a medium that is not viscous, in contrast to methods used in the state of the art.
- the CHO cell secretes more than on product.
- more than one anchoring/capturing means may be used in the invention, as is understood by a person of skill in the art.
- the invention provides a kit for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, comprising an anchoring/capturing means as described above and herein. Further components of the kit can be appropriate labels for the secreted product, and/or CHO cells. Optionally, the kit further comprises a magnetic labeling system.
- the invention provides the use of a kit as described above and herein for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, in particular in a method as described above and herein.
- FIG. 3 Schematic picture of a preferred embodiment of the present invention (Human Antibody CHO Capture System).
- an anchoring/capturing means also "a catch reagent" consisting of the ⁇ CHO antibody as the first antibody of the anchoring/capturing means and ⁇ human IgG antibody as the second antibody of the anchoring/capturing means was used.
- the cells were allowed to secrete humanized CD303 during a secretion period of 1 hour in warm CD CHO medium (37 °C).
- the secreted antibody was immobilized by the catch reagent near the cell surface and was detected with an ⁇ human Ig kappa-Biotin antibody.
- FIG. 4 Secretion assay and magnetic cell sorting Secretion assay was carried out on CHO pool 3/L cells. Shown are a negative control (A) and a positive control with staining of Tysabri-PE (B) as small-scale detection approaches without separation. The two fractions of the large-scale approach were the original fraction before separation (C) and the positive fraction of the second MS column (D). Dot plots A, C and D show staining with Anti-human Ig kappa on the x-axis (against the sideward scatter on the y-axis). All samples were measured at MACSQuant ® Analyzer and dead cells were excluded by a PI gate.
- mice were generated by standard immunization method of mice like it is described by Dzionek, A. et al, 2000, J. Immunol., 165: 6037-46 .
- immunization one non-stressed 8-week-old female Balb/c mouse was used.
- PBS steril 1x Phsophate buffered saline
- B-cells from the immunized mouse spleen were fused with the mouse myeloma cell line Sp2/0 Ag14 (AmCell) using polyethylene glycol 1500 (Roche). The fusion was done on day 24.
- CHO K1 cells (Invitrogen) per sample, different aCHO purified antibodies were titrated to determine binding. Therefore, pure ⁇ CHO antibodies were titrated in different concentrations for 10 minutes at 4 °C.
- PBS/EDTA/BSA abbreviated PEB
- detection was performed by isotype staining with rat a mouse IgG2b-R-Phycoerythrin (abbreviated PE; PE from Far East Bio- Tec Co) or rat ⁇ mouse IgG1-PE (both conjugates from Miltenyi Biotec) at a final dilution of 1/100 for 10 minutes at 4°C.
- PE mouse IgG2b-R-Phycoerythrin
- rat ⁇ mouse IgG1-PE both conjugates from Miltenyi Biotec
- transfected CHO DG44 cells (pool 3/L cells) secrete humanized CD303 antibody and had been gene-amplified with 80 nmol/l Methotrexate (Sigma).
- catch reagent consisting of an anchor and catch antibody were produced.
- the used catch reagent was composed of the CHO-specific antibody (clone HA3-21F5.6) and the Anti-human IgG antibody clone JH2-4F5.20.1 (both Miltenyi Biotec).
- SMCC succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate
- DTT dithiothreitol
- maleimides react with thiole groups at pH 6.5-7.5 to form stable thioether bonds. Coupling was performed for 30 minutes at 20 °C. The reaction was stopped with ⁇ -mercaptoethanol (abbreviated ß-ME; Merck)) and N-ethylmaleimide (abbreviated NEM; Sigma), incubating each for 15 minutes at 20°C.
- ß-ME ⁇ -mercaptoethanol
- NEM N-ethylmaleimide
- the ß-ME reacts with free maleimids, whereas the NEM reacts with free thioles. Buffer exchange to PBS/EDTA/Azide-buffer was performed with a PD-10 column (GE Healthcare) and protein-containing fractions were pooled.
- MicroBeads (abbreviated MB; Miltenyi Biotec) are superparamagnetic particles of approximately 50 nanometers in diameter.
- MACS ® Cell Separation Column (Miltenyi Biotec) is placed into a strong permanent magnet, the MACS Separator (Miltenyi Biotec), a high-gradient magnetic field is induced on the column matrix. This magnetic field within the MACS Cell Separation Column is strong enough to retain cells labeled with minimal amounts of MicroBeads.
- MS columns (Miltenyi Biotec) were used, which have a capacity of up to 1 x 10 7 magnetically labelled cells from up to 2 x 10 8 total cells.
- Fig. 3 The principle of the present invention (denoted also "Human Antibody CHO Capture System”) is schematically shown in Fig. 3 .
- the CHO pool 3/L cells were singularised with Trypsin/EDTA and cell concentration of viable cells was determined with a Neubauer chamber. Small-scale detection approaches with 10 6 cells as well as large-scale separation approaches with 10 7 cells were carried out. Staining volume for 10 6 cells was 100 ⁇ L, for 10 7 cells 1 mL.
- the CD303 specific ⁇ CHO / ⁇ human IgG "catch reagent" was diluted in cold CD CHO medium (4 °C) to 7.5 ⁇ g/mL and 10 6 cells were labeled with 100 ⁇ L staining solution for 5 minutes on ice. Afterwards, 10 mL (50 mL for 10 7 cells) of warm CD CHO medium (37 °C) were added and cells were allowed to secrete for 1 hour at 37 °C on a MACSmix Tube Rotator (Miltenyi Biotec). To stop secretion, 5 mL of cold PEB-buffer (4 °C) were added and cells were incubated for 5 minutes on ice.
- the ⁇ human Ig kappa-Biotin detection antibody (clone IS11-1G4.1.4; Miltenyi Biotec) was diluted with cold PEB-buffer (4 °C) to 2 ⁇ g/mL and cells were labeled with 100 ⁇ L for 10 minutes on ice. After a washing step with 1 mL cold PEB-buffer (4 °C), cells were stained for 10 minutes at 4 °C with ⁇ Biotin-PE (Miltenyi Biotec) in 110 ⁇ L, diluted 1:11 with cold PEB-buffer (4 °C).
- cells were washed with 1 mL cold PEB-buffer (4 °C), centrifuged (10'/ 100g/ 4 °C) and resuspended in 500 ⁇ l PEB. Cells were kept on ice until flow cytometric analysis and propidium iodide (Sigma) was added prior to measuring.
- negative control unstained cells were used, which were resuspended in 500 ⁇ L PEB-buffer after singularisation.
- Other negative controls were cells coated with catch reagent but without detection reagent and cells without catch reagent but stained with detection reagent without a secretion period or after a normal secretion period of 1 hour. Also cells coated with catch reagent and stained for ⁇ Biotin-PE were used as negative controls.
- ⁇ PE-MicroBeads were diluted in cold PEB buffer 1:5 and cells were labeled for 15 minutes on ice. Afterwards, cells were washed with 10 mL cold PEB-buffer and resuspended in 500 ⁇ L PEB.
- CHO pools 3/L cells of the logarithmic growth phase were singularised with Trypsin/EDTA and counted with the Neubauer chamber. Then, 2 x 10 5 viable cells were resuspended in a T75 flask containing 20 mL of new CD CHO Medium. After 48 hours, a 1 mL sample was taken to determine the cell number with the Neubauer chamber. Afterwards, the sample was centrifuged (5'/ 100g/ 20 °C), the supernatant collected and frozen at -20 °C.
- the antibody concentrations of the supernatants were determined by Enzyme Linked ImmunoSorbend Assay (ELISA).
- ELISA Enzyme Linked ImmunoSorbend Assay
- ⁇ human IgG (Beckman Coulter) was diluted in 0.05 mol/l Carbonate buffer, pH 9.6 (Sigma) to 5 ⁇ g/mL.
- 50 ⁇ L were added and incubated for 2 hours at 37 °C.
- the plate was washed with 3 x 350 ⁇ L 1x KP wash solution (DunnLabortechnik) with 10 seconds soaking between washes.
- 350 ⁇ L PBS/ BSA-buffer was added in each well and incubated for 1 h at RT.
- Tysabri (Biogen Idec) was used as the standard in the concentrations 0.781 ng/mL, 1.562 ng/mL, 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL and 25 ng/mL. Standard and samples were added in 50 ⁇ L duplicates and incubated for 1 hour at 37 °C. For two blanks 50 ⁇ L of PBS/BSA was added. After washing with 3 x 350 ⁇ L KP wash solution, ahuman Ig kappa-Horseradish Peroxidase (abbreviated HRP; Southern Biotech) was added according to manufacturer's instructions. The plate was incubated for 1 hour at 37 °C.
- HRP ahuman Ig kappa-Horseradish Peroxidase
- TMB ready to use ELISA substrate (3,3,5,5-Tetramethylbenzidine) (abbreviatedTMB; Serva) was added to each well.
- TMB trimethylbenzidine
- the reaction was stopped with 10 % sulfuric acid and absorbance was measured at 450 nm with the ELISA reader (MWG Biotec).
- cells need to be fixed with Inside Fix (3.7 % Formaldehyde solution; Miltenyi Biotec) and permeabilised with Inside Perm (0.5 % Saponin solution; MiltenyiBiotec).
- 10 6 cells (Pool3/L cells not enriched or enriched by Human Antibody CHO Capture System and afterwards cultivated for 16 days) were resuspended in 100 ⁇ L of PBS-buffer and mixed with 100 ⁇ L of Inside Fix. Cells were then incubated for 30 minutes at 20 °C. Next, 1 mL PEB-buffer was added and cells were pelleted (5'/ 200g/ 20°C). Fixed cells can be resuspendend in 100 ⁇ L PBS/EDTA-buffer and stored at 4 °C for one week.
- CHO pools 3/L cells containing a mixture of antibody secreting and non-secreting cells were subjected to separation by the Human Antibody CHO Capture System. Unseparated as well as enriched cells were further cultivated for 16 days and then analyzed for antibody production (table 1). As expected, the accumulated antibody was higher in enriched cells. Table 1. Antibody production of CHO cells without and after enrichment of cells in secretion assay according to a preferred embodiment of the invention tested by ELISA and intracellular staining. procedure accumulated antibody in well [ng/mL] producer rate [%] w/o separation 64.15 2.69 after separation 317.75 53.11
Abstract
- a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and
- a second antibody or a second antigen-binding fragment for binding the secreted product.
The invention further pertains to uses and methods including this anchoring/capturing means.
Description
- The invention pertains to an anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, as well as to uses thereof.
- The invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention pertains to an anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, as well as to uses thereof.
- Numerous attempts have been made to analyze populations of cells and to separate cells based on the products that they produce. Such approaches to cell analysis and separation are especially useful in assessing those cells which are capable of secreting a desired product (the "product"), or which are relatively high secretors of the product. These methods include cloning in microtiter plates and analysis of the culture supernatant for product, cloning in agar and analysis by methods for identification of the product of the localized cells; the identification methods include, for example, plaque assays and western blotting. Most methods for analysis and selection of cells based upon product secretion involve physically isolating the cell, followed by incubation under conditions that allow product secretion, and screening of the cell locations to detect the cell or cell clones that produce the product. When cells are in suspension, after the cells have secreted the product, the product diffuses from the cell without leaving a marker to allow identification of the cell from which it was secreted. Thus, secretor cells cannot be separated from non-secretor cells with these types of systems.
- The affinity matrix technology was established by Manz and coworkers (1995) to study the secretion of antibodies by hybridomas and cytokine secretion of activated T lymphocytes. To create an artificial affinity matrix on the cell surface, primary amine residues of surface molecules were biotinylated. Next, cells were labeled directly with an avidinated catch antibody, specific for the secreted molecule. Afterwards, cells were allowed to secrete in gelatine, a medium with decreased permeability to reduce diffusion of the secreted molecule. The catch antibody could then capture the secreted molecules in the vicinity of the cell surface. Secreting cells were subsequently labelled with fluorescent reagents, specific for the secreted molecule, to allow flow cytometric analysis and cell sorting. Borth et al. (Biotechnology and Bioengeneering, 2001, 71: 266-273) used this technique to select for high producing subclones of antibody-secreting CHO cells. CHO cells provide glycosylation patterns of the synthesized proteins that are similar to those provided in human cells. Therefore, such proteins are particularly suitable as therapeutic proteins.
- A further development of this technique was the use of an (neutr)avidin bridge and a biotinylated antibody instead of an avidinated antibody to maximize the binding capacity of the matrix. Furthermore, the CHO cells were embedded in medium with only 10 % gelatine. Holmes and Al-Rubeai (1999) named this method the affinity capture surface display (ACSD).
- An alteration of the ACSD method was introduced by Carroll and Al-Rubeai (2005) that replaced fluorescent activated cell sorting by magnetic activated cell sorting to improve cell viablity of fragile cells.
- In these approaches, the extracellular surface of the CHO cells is chemically treated in order to allow for a capturing moiety to bind to the extracellular surface of the CHO cells. Moreover, these approaches are laborious and thus disadvantageous.
- Accordingly, it was an object of the present invention to provide an alternative approach for selecting or analyzing a CHO cell according to a product secreted by the CHO cell.
- The present invention provides methods for detecting, analyzing and separating antigen-stimulated T cells on the basis of secreted product, where the product is secreted. The methods are based on capture and relocation to the cell surface of the secreted product. The captured product permits the cell to be detected, analyzed and, if desired, sorted, according to the presence, absence or amount of the product present. The means of capture comprises a product-specific anchoring/capturing means.
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as,"Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M. J. Gait, ed., 1984); "Animal Cell Culture" (R. I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D. M. Weir & C. C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J. M. Miller & M. P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F. M. Ausubel et al., eds., 1987, and periodic updates); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994); and "Current Protocols in Immunology" (J. E. Coligan et al., eds., 1991).
- Cell sorting and cell analysis methods are known in the art and are described in, for example, The Handbook of Experimental Immunology, or) and Flow Cytometry and Cell Sorting (A. Radbruch, editor, Springer Verlag, 1992).
- The invention provides, in a first aspect, an anchoring/capturing means for selecting or analyzing a CHO cell according to a product that is being synthesized and secreted by the CHO cell into a medium surrounding the cell. According to the invention, this anchoring/capturing means comprises
- a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and
- a second antibody or a second antigen-binding fragment for binding the secreted product.
- The term "selecting" may comprise also enriching and isolating. The term"substantially enriched"as used herein, indicates that a cell population is at least about 50-fold, more preferably at least about 500-fold, and even more preferably at least about 5000-fold or more enriched from an original mixed cell population comprising the desired cell population.
- The present invention provides methods for obtaining a cell population enriched in CHO cells which secrete a product.
- As the anchoring/capturing means may comprise a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antigen-binding fragment for binding the secreted product, the anchoring/capturing means can be, in one embodiment of the invention, a bispecific antibody.
- "Bispecific antibody" and "bispecific antibodies," also known as bifunctional antibodies, intends antibodies that recognize two different antigens by virtue of possessing at least one first antigen combining site specific for a first antigen or hapten, and at least one second antigen combining site specific for a second antigen or hapten. Such antibodies can be produced by recombinant DNA methods or include, but are not limited to, antibodies chemically by methods known in the art.
- Chemically created bispecific antibodies that have been reduced and reformed so as to retain their bivalent characteristics and antibodies that have been chemically coupled so that they have at least two antigen recognition sites for each antigen.
- In a preferred embodiment, this anchoring/capturing means is a conjugate of at least two antibodies or antigen-binding fragments that were chemically joined, preferably at the Fc moiety. Methods for conjugating are known to a person of skill in the art.
- Preferably, the first antibody or the first antigen-binding fragment of the anchoring/capturing means binds specifically to a surface molecule of the CHO cell, thereby anchoring the anchoring/capturing means to the CHO cell. In order for the second antibody or a second antigen-binding fragment to be able to binding the product from the CHO cell, the first antibody or antigen-binding fragment must be oriented such to the second antibody or antigen-binding fragment that binding of the product is not sterically hindered.
- It is further preferred that the first antibody or the first antigen-binding fragment for anchoring the anchoring/capturing means to the extracellular surface of the CHO cell is a monoclonal antibody or an antigen-binding fragment thereof, in particular the monoclonal antibody HA3-21F5.6 or an antigen-binding fragment thereof.
- Most preferred is an anchoring/capturing means, wherein the first antibody is the monoclonal antibody HA3-21F5.6 that is being secreted by the hybridoma cell line that was deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany, on April 30, 2010. The generation of this first antibody is described in the examples.
- The first antibody recognizes in a preferred embodiment a target on the extracellular surface of the CHO cell that is constitutively expressed. In another embodiment, the first antibody recognizes a target on the extracellular surface of the CHO cell that is expressed upon induction of the cell with a chemical inducer.
- The second antibody or the second antigen-binding fragment of the anchoring/capturing means is, in a preferred embodiment, specifically binding a CD303 (BDCA-2) antibody as the product. CD303 (BDCA-2) is a Ca2+-dependent type II C-type lectin that is specifically expressed by human plasmacytoid dendritic cells (Rock et al., 2007).
- In a second aspect, the invention provides the use of an anchoring/capturing means as described above and herein for selecting or analyzing a CHO cell according to a product secreted by the CHO cell.
- In a third aspect, the invention provides CHO cell bound to an anchoring/capturing means as described above and herein.
- In a fourth aspect, the invention provides a method for selecting or analyzing a CHO cell according to a product secreted by the CHO cell. The method comprises the following steps:
- (a) binding an anchoring/capturing means to the surface of the CHO cell for capturing the product,
wherein the anchoring/capturing means comprises- a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and
- a second antibody or a second antigen-binding fragment for binding the secreted product;
- (b) culturing the cell under conditions wherein the product is secreted and specifically bound to the second antibody or to the second antigen-binding fragment of the anchoring/capturing means;
- (c) labeling the product with a detectable label; and
- (d) selecting or analyzing the cell on the basis of the bound and labeled product.
- In contrast to other systems in the state of the art for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, the present invention does not depend on a chemical modification of molecules on the surface of the CHO cell. Moreover, no streptavidin, avidin or alike need be used for direct treatment of the CHO cell.
- In a preferred embodiment of the method, the cells that have a secreted product bound to the second antibody or the second antigen-binding fragment of the anchoring/capturing means are not lysed as part of the selection or analysis but remain intact.
- The product that is being secreted from the CHO cell is preferably is a protein, in particular an antibody or an antigen-binding fragment of an antibody. The antigen-binding fragment can be chosen from the group consisting of whole antibodies, bispecific antibodies, chimeric antibodies, Fab, F (ab')2, single chain V region fragments (scFv), fusion proteins, aptomers, carbohydrates, and lectins.
- A preferred secreted antibody is an antibody against the molecule CD303 (BDCA-2), which is known in the art.
- If the secreted product is an antibody, then it is preferably chosen from the group consisting of humanized antibodies, chimeric antibodies, human antibodies, and antigen-binding fragments thereof.
- After binding of the product to the CHO cell via the anchoring/capturing means, the cell may be detectably labeled, e.g. using a third or forth antibody, each antibody carrying a detectable label (the same or different labels). By using different antibodies, a stronger signal for detection may be generated.
- The detectable label may comprise at least one from the group consisting of magnetic particles, fluorophores, radioactive isotopes, haptenes, and chromophores. The labeled cells can then be separated using standard cell sorting techniques based on these labels. Such techniques include, but are not limited to, flow cytometry, FACS, high gradient magnetic separation, centrifugation. When the label is a magnetic particle, magnetic cell sorting (MACS) can be used to identify CHO cells excreting the product or excreting the product at certain levels. Thereby, CHO cell lines with certain secretion characteristics can be obtained, such as highly excreting CHO cell lines.
- Preferred magnetic labeling methods include colloidal superparamagnetic particles in a size range of 5 to 200 nm, preferably in a size of 10 to 100 nm. These magnetic particles allow a quantitative magnetic labeling of cells, thus the amount of coupled magnetic label is proportional to the amount of bound product, and the magnetic separation methods are sensitive to different amounts of product secretion.
- Colloidal particles with various specificities are known in the art, and are available, for example, through Miltenyi Biotec GmbH. The use of immunospecific fluorescent or magnetic liposomes can also be used for quantitative labeling of captured product.
- In these cases, the liposomes contain magnetic material and/or fluorescent dyes conjugated with antibody on their surfaces, and magnetic separation is used to allow optimal separation between nonproducing, low producing, and high producing cells.
- The magnetic separation can be accomplished with high efficiency by combining a second force to the attractive magnetic force, causing a separation based upon the different strengths of the two opposed forces. Typical opposed forces are, for example, forces induced by magnetic fluids mixed in the separation medium in the magnetic separation chamber, gravity, and viscous forces induced by flow speed of medium relative to the cell. Any magnetic separation method, preferably magnetic separation methods allowing quantitative separation will be used. It is also contemplated that different separation methods can be combined, for example, magnetic cell sorting can be combined with FACS, to increase the separation quality or to allow sorting by multiple parameters.
- Preferred techniques include high gradient magnetic separation (HGMS), a procedure for selectively retaining magnetic materials in a chamber or column disposed in a magnetic field. In one application of this technique the product is labeled by attaching it to a magnetic particle. The attachment is generally through association of the product with a label moiety which is conjugated to a coating on the magnetic particle which provides a functional group for the conjugation. The captured product thus coupled to a magnetic "label", is suspended in a fluid, which is then applied to the chamber. In the presence of a magnetic gradient supplied across the chamber, the magnetically labeled target cell is retained in the chamber; if the chamber contains a matrix, it becomes associated with the matrix. Cells which do not have or have only a low amount of magnetic labels pass through the chamber.
- The retained cells can then be eluted by changing the strength of, or by eliminating, the magnetic field or by introducing a magnetic fluid. The selectivity for a captured product is supplied by the label moiety conjugated either directly or indirectly to the magnetic particle or by using a primary antibody and a magnetic particle recognizing the primary antibody. The chamber across which the magnetic field is applied is often provided with a matrix of a material of suitable magnetic susceptibility to induce a high magnetic field gradient locally in the camber in volumes close to the surface of the matrix. This permits the retention of fairly weakly magnetized particles. Publications describing a variety of HGMS systems are known in the art, and include, for example,
U. S. Patent No. 4,452,773 ,U. S. Patent No. 4,230,685 ,PCT application W085/04330 U. S. Patent No. 4,770,183 , andPCT/EP89/01602 ; systems are also described inU. S. Patent Nos. 5,411,863 ;5,543,289 ;5,385,707 ; and5,693,539 , which are commonly owned and hereby incorporated herein by reference. - These conditions are known to those of skill in the art and include, inter alia, appropriate temperature, pH, and concentrations of salts, growth factors and substrates in the incubation medium, as well as the appropriate concentrations of gas in the gaseous phase. When it is desirable to distinguish between high and low producer cells, the time of incubation is such that product secretion by the cells is still in a linear phase. The appropriate conditions can be determined empirically and such a determination is within the skill of one in the art.
- Additionally, cell secretion can be modified, that is, upregulated, induced, or reduced using a biological modifier. The biological modifiers can be added at any time but are preferably added to the incubation medium. Alternatively, the cells can be pretreated with these agents or cells prior to the incubation step. Suitable biological modifiers include, but are not limited to, molecules and other cells.
- Suitable molecules include, but are not limited to, drugs, cytokines, small molecules, hormones, combinations of interleukins, lectins and other stimulating agents, e.g., PMA, LPS, bispecific antibodies and other agents that modify cellular functions or protein expression.
- The culturing conditions are also such that product is essentially not captured or is captured to a much lesser extent by another cell, so as to distinguish non-producing cells from product producing cells, or high producers from low producers. Generally the incubation time is between five minutes and ten hours, and is more usually between one and five hours. The incubation medium can optionally include a substance that slows diffusion of the product from the producer cell.
- In a preferred embodiment, the CHO cell is cultured in a medium that is not viscous, in contrast to methods used in the state of the art.
- It is possible that the CHO cell secretes more than on product. In that case, more than one anchoring/capturing means may be used in the invention, as is understood by a person of skill in the art.
- In a fifth aspect, the invention provides a kit for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, comprising an anchoring/capturing means as described above and herein. Further components of the kit can be appropriate labels for the secreted product, and/or CHO cells. Optionally, the kit further comprises a magnetic labeling system.
- In a sixth aspect, the invention provides the use of a kit as described above and herein for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, in particular in a method as described above and herein.
-
-
Figure 1 . Titration of first antibodies for anchoring to the extracellular surface of the CHO cell as part of the anchoring/capturing means (αCHO purified antibodies). -
Figure 2 . Strategy of magnetic separation of magnetically labeled CHO cells with two MS columns. - Cells were labeled with antibody-MicroBead conjugates (A) and applied onto the first MS column. During the washing steps, unlabelled cells passed through the column into the negative fraction (B). The first MS column was flushed out into the second MS column using 1 mL PBS/EDTA/BSA buffer and the plunger (C). Washing of the second MS column washed out remaining unlabelled cells into the negative fraction 2 (C). Finally, the second MS column was removed from the magnet and flushed out with 0.5 mL buffer, yielding the
positive fraction 2. -
Figure 3 . Schematic picture of a preferred embodiment of the present invention (Human Antibody CHO Capture System). For labeling of the CHO cells, an anchoring/capturing means (also "a catch reagent") consisting of the αCHO antibody as the first antibody of the anchoring/capturing means and αhuman IgG antibody as the second antibody of the anchoring/capturing means was used. The cells were allowed to secrete humanized CD303 during a secretion period of 1 hour in warm CD CHO medium (37 °C). The secreted antibody was immobilized by the catch reagent near the cell surface and was detected with an αhuman Ig kappa-Biotin antibody. To fluorescently stain the cells, conjugates of an αBiotin antibody coupled to R-Phycoerythrin (PE) were used. Cells were magnetically labeled with an αPE-MicroBead conjugate. Separation was performed with 2 MS columns. -
Figure 4 . Secretion assay and magnetic cell sorting
Secretion assay was carried out on CHO pool 3/L cells. Shown are a negative control (A) and a positive control with staining of Tysabri-PE (B) as small-scale detection approaches without separation. The two fractions of the large-scale approach were the original fraction before separation (C) and the positive fraction of the second MS column (D). Dot plots A, C and D show staining with Anti-human Ig kappa on the x-axis (against the sideward scatter on the y-axis). All samples were measured at MACSQuant® Analyzer and dead cells were excluded by a PI gate. - As CHO cells in suspension retained some of their adherent growth characteristics and tended to clump in suspension, treatment of cells was necessary to receive a single-cell suspension. Therefore, cells of a defined volume were pelleted by centrifugation (10'/ 100g/ 20 °C). Afterwards, the pellet was resuspended in 10 % of Trypsin/ EDTA (Sigma) for approximately 5 minutes at room temperature (abbreviated RT). Progress of singularisation was continuously observed by light microscopy. When singularisation was complete, CD CHO medium (Gibco) was added up to the previous volume. After pelleting (10'/ 100g/ 20 °C), cells were resuspended in fresh CD CHO medium. In all experiments, cells were prediluted to densities allowing linear growth to maintain high cell viability one day before experiment.
- The αCHO antibodies were generated by standard immunization method of mice like it is described by Dzionek, A. et al, 2000, J. Immunol., 165: 6037-46.
For immunization, one non-stressed 8-week-old female Balb/c mouse was used. Onday - On 106 CHO K1 cells (Invitrogen) per sample, different aCHO purified antibodies were titrated to determine binding. Therefore, pure αCHO antibodies were titrated in different concentrations for 10 minutes at 4 °C. After washing with 1 mL PBS/EDTA/BSA (abbreviated PEB) -buffer, detection was performed by isotype staining with rat a mouse IgG2b-R-Phycoerythrin (abbreviated PE; PE from Far East Bio- Tec Co) or rat α mouse IgG1-PE (both conjugates from Miltenyi Biotec) at a final dilution of 1/100 for 10 minutes at 4°C. For flow cytometric analysis MACSQuant® Analyzer (Miltenyi Biotec) was used. The analyses were done using MACSQuantify™ Software (Miltenyi Biotec) and were restricted to viable cells.
- The same αCHO antibody clones were also tested on untransfected CHO DG44, CHO Dukx B11 (ATCC) and transfected CHO DG44 cells (pool 3/L cells) and showed positive staining of all three additional CHO cell lines. Transfected CHO DG44 cells (pool 3/L cells) secrete humanized CD303 antibody and had been gene-amplified with 80 nmol/l Methotrexate (Sigma).
- Two antibodies are linked covalently by use of functional groups. Thus, catch reagent consisting of an anchor and catch antibody were produced. The used catch reagent was composed of the CHO-specific antibody (clone HA3-21F5.6) and the Anti-human IgG antibody clone JH2-4F5.20.1 (both Miltenyi Biotec).
- First, catch antibody were activated with succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (abbreviated SMCC; Pierce) for 1 h at 20 °C. Afterwards, the reaction was stopped and SMCC was depleted by buffer exchange with a Sephadex column (GE Healthcare). Protein containing fractions were determined with Coomassie (Pierce) staining and pooled. To control activation, coupled maleimide groups were determined with a backward titration using cysteaminium chlorid (Merck). The cysteamin reacted with the maleimide groups of the activated antibody and the remaining thioles were detected with Ellman's reagent (Pierce) at OD412.
- Second, reduction of anchor antibody was performed with 20 mmol/l dithiothreitol (abbreviated DTT; Sigma) for 1h at 20 °C. The excessive DTT was then removed by buffer exchange with a Sephadex column. Protein containing fractions were defined with Coomassie and pooled. The amount of thioles per molecule antibody was determined with Ellman's reagent at OD412.
- Third, maleimides react with thiole groups at pH 6.5-7.5 to form stable thioether bonds. Coupling was performed for 30 minutes at 20 °C. The reaction was stopped with β-mercaptoethanol (abbreviated ß-ME; Merck)) and N-ethylmaleimide (abbreviated NEM; Sigma), incubating each for 15 minutes at 20°C. The ß-ME reacts with free maleimids, whereas the NEM reacts with free thioles. Buffer exchange to PBS/EDTA/Azide-buffer was performed with a PD-10 column (GE Healthcare) and protein-containing fractions were pooled.
- Cells with distinct characteristics can be separated easily using magnetic activated cell sorting (Miltenyi et al., 1990). For the magnetic labelling of cells antibody-MicroBead conjugates are used. MicroBeads (abbreviated MB; Miltenyi Biotec) are superparamagnetic particles of approximately 50 nanometers in diameter. When the MACS® Cell Separation Column (Miltenyi Biotec) is placed into a strong permanent magnet, the MACS Separator (Miltenyi Biotec), a high-gradient magnetic field is induced on the column matrix. This magnetic field within the MACS Cell Separation Column is strong enough to retain cells labeled with minimal amounts of MicroBeads.
- For all separations, MS columns (Miltenyi Biotec) were used, which have a capacity of up to 1 x 107 magnetically labelled cells from up to 2 x 108 total cells.
- Before use, columns were equilibrated with 0.5 mL PEB-buffer. The so-called original fraction containing both labeled and unlabelled cells (
Figure 2 A) was applied on the column. The unlabelled cells, which passed through were collected and the column was washed 3 times with 0.5 mL PEB-buffer. Cells that are labeled with the antibody-MicroBeads conjugates (Miltenyi Biotec) were retained in the column, but unlabelled cells passed through the column and could be collected as the negative fraction (Figure 2 B) . After the column was removed form the magnet, retained cells were eluted with 1 mL buffer as the positively selected cell fraction using the plunger. However, to increase purity, a second MS column was used and cells were directly flushed out of the first column into the second column. Trapped unlabelled cells were then removed by washing with 3 x 0.5 mL PEB buffer (Figure 2 C) . Finally, the labeled cells were flushed out of the second column with 0.5 mL buffer and collected as the positive fraction 2 (Figure 2 D) . - The principle of the present invention (denoted also "Human Antibody CHO Capture System") is schematically shown in
Fig. 3 . - The CHO pool 3/L cells were singularised with Trypsin/EDTA and cell concentration of viable cells was determined with a Neubauer chamber. Small-scale detection approaches with 106 cells as well as large-scale separation approaches with 107 cells were carried out. Staining volume for 106 cells was 100 µL, for 107
cells 1 mL. - The CD303 specific αCHO / αhuman IgG "catch reagent" (anchoring/capturing means) was diluted in cold CD CHO medium (4 °C) to 7.5 µg/mL and 106 cells were labeled with 100 µL staining solution for 5 minutes on ice. Afterwards, 10 mL (50 mL for 107 cells) of warm CD CHO medium (37 °C) were added and cells were allowed to secrete for 1 hour at 37 °C on a MACSmix Tube Rotator (Miltenyi Biotec). To stop secretion, 5 mL of cold PEB-buffer (4 °C) were added and cells were incubated for 5 minutes on ice. Thereafter, cells were centrifuged (10'/ 100g/ 4°C) and the supernatant was removed. The α human Ig kappa-Biotin detection antibody (clone IS11-1G4.1.4; Miltenyi Biotec) was diluted with cold PEB-buffer (4 °C) to 2 µg/mL and cells were labeled with 100 µL for 10 minutes on ice. After a washing step with 1 mL cold PEB-buffer (4 °C), cells were stained for 10 minutes at 4 °C with αBiotin-PE (Miltenyi Biotec) in 110 µL, diluted 1:11 with cold PEB-buffer (4 °C). Afterwards, cells were washed with 1 mL cold PEB-buffer (4 °C), centrifuged (10'/ 100g/ 4 °C) and resuspended in 500 µl PEB. Cells were kept on ice until flow cytometric analysis and propidium iodide (Sigma) was added prior to measuring.
- As a negative control, unstained cells were used, which were resuspended in 500 µL PEB-buffer after singularisation. Other negative controls were cells coated with catch reagent but without detection reagent and cells without catch reagent but stained with detection reagent without a secretion period or after a normal secretion period of 1 hour. Also cells coated with catch reagent and stained for αBiotin-PE were used as negative controls.
- Positive controls were stained with catch reagent and with Tysabri-PE (Miltenyi Biotec) for 10 minutes on ice without a secretion period or with a secretion period of 1 hour. Tysabri (= Natalizumab; Biogen Idec) is a humanized IgG4 antibody for therapeutic use.
- After the staining of antibody-secreting cells with a human Igkappa-Biotin and αBiotin-PE, large-scale separation approaches were labelled magnetically using the αPE-MicroBead conjugate. Therefore, αPE-MicroBeads were diluted in cold PEB buffer 1:5 and cells were labeled for 15 minutes on ice. Afterwards, cells were washed with 10 mL cold PEB-buffer and resuspended in 500 µL PEB.
- Before magnetic activated cell sorting, a 10 µL aliquot of the original fraction was preserved for flow cytometric analysis and diluted 1:20 with cold PEB-buffer.
- The separation was carried out using 2 MS columns according to the protocol described in
experiment 5. After separation, cells of the original fraction and the second positive fraction were subjected to flow cytometric analysis. - CHO pools 3/L cells of the logarithmic growth phase were singularised with Trypsin/EDTA and counted with the Neubauer chamber. Then, 2 x 105 viable cells were resuspended in a T75 flask containing 20 mL of new CD CHO Medium. After 48 hours, a 1 mL sample was taken to determine the cell number with the Neubauer chamber. Afterwards, the sample was centrifuged (5'/ 100g/ 20 °C), the supernatant collected and frozen at -20 °C.
- The antibody concentrations of the supernatants were determined by Enzyme Linked ImmunoSorbend Assay (ELISA). For coating, αhuman IgG (Beckman Coulter) was diluted in 0.05 mol/l Carbonate buffer, pH 9.6 (Sigma) to 5 µg/mL. In each well, 50 µL were added and incubated for 2 hours at 37 °C. The plate was washed with 3 x 350 µL 1x KP wash solution (DunnLabortechnik) with 10 seconds soaking between washes. For blocking of potential unspecific binding sites, 350 µL PBS/ BSA-buffer was added in each well and incubated for 1 h at RT. Then, plates were washed with 3 x 350 µL KP wash solution. The cell culture supernatant was diluted with PBSBSA-buffer to fall in the linear portion of the standard curve. For estimated antibody concentrations of 0.02 - 0.5 µg/mL the sample was diluted 1:20, 1:40, 1:50 and 1:60. If the estimated antibody concentrations were 0.5 - 5 µg/mL, the sample was diluted 1:200, 1:400, 1:500 and 1:600. Tysabri (Biogen Idec) was used as the standard in the concentrations 0.781 ng/mL, 1.562 ng/mL, 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL and 25 ng/mL. Standard and samples were added in 50 µL duplicates and incubated for 1 hour at 37 °C. For two blanks 50 µL of PBS/BSA was added. After washing with 3 x 350 µL KP wash solution, ahuman Ig kappa-Horseradish Peroxidase (abbreviated HRP; Southern Biotech) was added according to manufacturer's instructions. The plate was incubated for 1 hour at 37 °C. Then, the plate was washed three times and 50 µL TMB ready to use ELISA substrate (3,3,5,5-Tetramethylbenzidine) (abbreviatedTMB; Serva) was added to each well. The reaction was stopped with 10 % sulfuric acid and absorbance was measured at 450 nm with the ELISA reader (MWG Biotec).
- For the calculation of the antibody concentration, a standard curve was created.
- To allow antibody binding to intracellular proteins, cells need to be fixed with Inside Fix (3.7 % Formaldehyde solution; Miltenyi Biotec) and permeabilised with Inside Perm (0.5 % Saponin solution; MiltenyiBiotec).
- First, 106 cells (Pool3/L cells not enriched or enriched by Human Antibody CHO Capture System and afterwards cultivated for 16 days) were resuspended in 100 µL of PBS-buffer and mixed with 100 µL of Inside Fix. Cells were then incubated for 30 minutes at 20 °C. Next, 1 mL PEB-buffer was added and cells were pelleted (5'/ 200g/ 20°C). Fixed cells can be resuspendend in 100 µL PBS/EDTA-buffer and stored at 4 °C for one week.
- For staining, cells were washed with 1 mL Inside Perm buffer and pelleted (5'/ 200g/ 20 °C). Afterwards, cells were pre-incubated with 100 µL Inside Perm for 20 minutes at 20 °C. Following fluorescent antibodies were used: α human Ig kappa-PE or -APC and α human IgG4-FITC (positive staining) and α human Ig lambda-PE or APC and α human IgG2b-FITC (negative staining) All conjugated from Miltenyi Biotec. Fluorochromes are added and incubated for 20 minutes at 20 °C. Cells were washed with 1 mL Inside Perm and resuspended in 500 µL PEB-buffer. Analysis was performed by flow cytometry.
- As described, CHO pools 3/L cells containing a mixture of antibody secreting and non-secreting cells were subjected to separation by the Human Antibody CHO Capture System. Unseparated as well as enriched cells were further cultivated for 16 days and then analyzed for antibody production (table 1). As expected, the accumulated antibody was higher in enriched cells.
Table 1. Antibody production of CHO cells without and after enrichment of cells in secretion assay according to a preferred embodiment of the invention tested by ELISA and intracellular staining. procedure accumulated antibody in well [ng/mL] producer rate [%] w/o separation 64.15 2.69 after separation 317.75 53.11
Claims (15)
- An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, comprising- a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and- a second antibody or a second antigen-binding fragment for binding the secreted product.
- The anchoring/capturing means of claim 1, wherein the first antibody or the first antigen-binding fragment of the anchoring/capturing means binds specifically to a surface molecule of the CHO cell.
- The anchoring/capturing means of claim 1 or 2, wherein the first antibody or the first antigen-binding fragment for anchoring the anchoring/capturing means to the extracellular surface of the CHO cell is a monoclonal antibody or an antigen-binding fragment thereof, in particular the monoclonal antibody HA3-21F5.6 or an antigen-binding fragment thereof.
- The anchoring/capturing means of claim 1 to 3, wherein the first antibody is the monoclonal antibody HA3-21F5.6 and is being secreted by the hybridoma cell line that was deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany, on April 30, 2010.
- The anchoring/capturing means of claims 1 to 4, wherein the second antibody or the second antigen-binding fragment of the anchoring/capturing means is specifically binding an antibody as the product, in particular a CD303 (BDCA-2) antibody as the product.
- Use of an anchoring/capturing means of claims 1 to 5 for selecting or analyzing a CHO cell according to a product secreted by the CHO cell.
- A CHO cell bound to an anchoring/capturing means of claims 1 to 5.
- A method for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, comprising:(a) binding an anchoring/capturing means to the surface of the CHO cell for capturing the product,
wherein the anchoring/capturing means comprises- a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and- a second antibody or a second antigen-binding fragment for binding the secreted product;(b) culturing the cell under conditions wherein the product is secreted and specifically bound to the second antibody or to the second antigen-binding fragment of the anchoring/capturing means;(c) labeling the product with a detectable label; and(d) selecting or analyzing the cell on the basis of the bound and labeled product. - The method of claim 8, wherein the cells having product bound to the second antibody or the second antigen-binding fragment of the anchoring/capturing means are not lysed as part of the selection or analysis.
- The method of claim 8 or 9, wherein the secreted product is a protein, in particular an antibody or an antigen-binding fragment of an antibody.
- The method of claims 8 to 10, wherein the secreted product is an antibody that is chosen from the group consisting of humanized antibodies, chimeric antibodies, human antibodies, or antigen-binding fragments thereof.
- The method of claims 8 to 11, wherein the detectable label comprises at least one from the group consisting of magnetic particles, fluorophores, radioactive isotopes, haptenes and chromophores.
- The method of claims 8 to 12, wherein the secreted product is a CD303 (BDCA-2) antibody or a fragment thereof.
- A kit for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, comprising- an anchoring/capturing means of claims 1 to 5.
- Use of a kit of claim 14 for selecting or analyzing a CHO cell according to a product secreted by the CHO cell, in particular in a method of claims 8 to 13.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10004611.9A EP2390661B1 (en) | 2010-05-02 | 2010-05-02 | An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell |
US13/098,498 US8663985B2 (en) | 2010-05-02 | 2011-05-02 | Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10004611.9A EP2390661B1 (en) | 2010-05-02 | 2010-05-02 | An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2390661A1 true EP2390661A1 (en) | 2011-11-30 |
EP2390661B1 EP2390661B1 (en) | 2015-06-24 |
Family
ID=42740342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10004611.9A Active EP2390661B1 (en) | 2010-05-02 | 2010-05-02 | An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell |
Country Status (2)
Country | Link |
---|---|
US (1) | US8663985B2 (en) |
EP (1) | EP2390661B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012083020A2 (en) | 2010-12-15 | 2012-06-21 | Cytosed, Inc. | Antibody-linked immuno-sedimentation agent and method of isolating a target from a sample using same |
EP3601558A4 (en) | 2017-03-24 | 2021-01-06 | Lankenau Institute for Medical Research | Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230685A (en) | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
WO1985004330A1 (en) | 1984-03-29 | 1985-10-10 | Nyegaard & Co A/S | Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents |
US4770183A (en) | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5385707A (en) | 1988-12-28 | 1995-01-31 | Stefan Miltenyi | Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same |
US5411863A (en) | 1988-12-28 | 1995-05-02 | S. Miltenyi | Methods and materials for improved high gradient magnetic separation of biological materials |
DE19900635A1 (en) * | 1999-01-11 | 2000-07-13 | Deutsches Krebsforsch | Selection of monoclonal antibodies |
WO2002057423A2 (en) * | 2001-01-16 | 2002-07-25 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
WO2003012449A2 (en) * | 2001-07-27 | 2003-02-13 | Lonza Group Ag | Method for selecting antibody expressing cells |
US6576428B1 (en) * | 1998-05-11 | 2003-06-10 | Miltenyi Biotech Gmbh | Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof |
WO2003099996A2 (en) * | 2002-05-22 | 2003-12-04 | Biogen Idec Ma Inc. | Detection of secreted polypeptides |
US7166423B1 (en) * | 1992-10-21 | 2007-01-23 | Miltenyi Biotec Gmbh | Direct selection of cells by secretion product |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
-
2010
- 2010-05-02 EP EP10004611.9A patent/EP2390661B1/en active Active
-
2011
- 2011-05-02 US US13/098,498 patent/US8663985B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230685A (en) | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
WO1985004330A1 (en) | 1984-03-29 | 1985-10-10 | Nyegaard & Co A/S | Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents |
US4770183A (en) | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5543289A (en) | 1988-12-28 | 1996-08-06 | Miltenyi; Stefan | Methods and materials for improved high gradient magnetic separation of biological materials |
US5411863A (en) | 1988-12-28 | 1995-05-02 | S. Miltenyi | Methods and materials for improved high gradient magnetic separation of biological materials |
US5385707A (en) | 1988-12-28 | 1995-01-31 | Stefan Miltenyi | Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same |
US5693539A (en) | 1988-12-28 | 1997-12-02 | Miltenyi; Stefan | Methods for coating metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same |
US7166423B1 (en) * | 1992-10-21 | 2007-01-23 | Miltenyi Biotec Gmbh | Direct selection of cells by secretion product |
US6576428B1 (en) * | 1998-05-11 | 2003-06-10 | Miltenyi Biotech Gmbh | Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof |
DE19900635A1 (en) * | 1999-01-11 | 2000-07-13 | Deutsches Krebsforsch | Selection of monoclonal antibodies |
WO2002057423A2 (en) * | 2001-01-16 | 2002-07-25 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
WO2003012449A2 (en) * | 2001-07-27 | 2003-02-13 | Lonza Group Ag | Method for selecting antibody expressing cells |
WO2003099996A2 (en) * | 2002-05-22 | 2003-12-04 | Biogen Idec Ma Inc. | Detection of secreted polypeptides |
Non-Patent Citations (12)
Title |
---|
A.S.H. HOCH: "Entwicklung eines Expressionssystems für rekombinante Antikörper in mammalischen Zellen", 20 May 2010 (2010-05-20), XP002602569, Retrieved from the Internet <URL:HTTP://WWW.DIGIBIB.TU-BS.DE/?DOCID=00033488> [retrieved on 20100924] * |
AKSELBAND YEVGENYA ET AL: "Isolation of rare isotype switch variants in hybridoma cell lines using an agarose gel microdrop-based protein secretion assay.", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES OCT 2003 LNKD- PUBMED:15090234, vol. 1, no. 5, October 2003 (2003-10-01), pages 619 - 626, XP002602570, ISSN: 1540-658X * |
BORTH ET AL., BIOTECHNOLOGY AND BIOENGENEERING, vol. 71, 2001, pages 266 - 273 |
BREZINSKY S C G ET AL: "A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL LNKD- DOI:10.1016/S0022-1759(03)00108-X, vol. 277, no. 1-2, 1 June 2003 (2003-06-01), pages 141 - 155, XP004430554, ISSN: 0022-1759 * |
BROSTERHUS H ET AL: "ENRICHMENT AND DETECTION OF LIVE ANTIGEN-SPECIFIC CD4+ AND CD8+ T CELLS BASED ON CYTOKINE SECRETION", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE LNKD- DOI:10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3, vol. 29, no. 12, 1 December 1999 (1999-12-01), pages 4053 - 4059, XP000971503, ISSN: 0014-2980 * |
CARON ANTOINE W ET AL: "Fluorescent labeling in semi-solid medium for selection of mammalian cells secreting high-levels of recombinant proteins", BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB LNKD- DOI:10.1186/1472-6750-9-42, vol. 9, no. 1, 11 May 2009 (2009-05-11), pages 42, XP021058100, ISSN: 1472-6750 * |
DZIONEK A ET AL: "BDCA-2, BDCA-3, AND BDCA-4: THREE MARKERS FOR DISTINCT SUBSETS OF DENDRITIC CELLS IN HUMAN PERIPHERAL BLOOD", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 165, no. 11, 1 December 2000 (2000-12-01), pages 6037 - 6046, XP000986292, ISSN: 0019-2805 * |
DZIONEK, A. ET AL., J. IMMUNOL., vol. 165, 2000, pages 6037 - 46 |
HANANIA ELIE G ET AL: "Automated in situ measurement of cell-specific antibody secretion and laser-mediated purification for rapid cloning of highly-secreting producers", BIOTECHNOLOGY AND BIOENGINEERING, vol. 91, no. 7, September 2005 (2005-09-01), pages 872 - 876, XP002602571, ISSN: 0006-3592 * |
HOLMES P ET AL: "Improved cell line development by a high throughput affinity capture surface display technique to select for high secretors", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL LNKD- DOI:10.1016/S0022-1759(99)00181-7, vol. 230, no. 1-2, 19 November 1999 (1999-11-19), pages 141 - 147, XP002250983, ISSN: 0022-1759 * |
MANZ R A ET AL: "Flow cytometric analysis of antibody-secreting cells", CYTOMETRY, ALAN LISS, NEW YORK, US, no. suppl. 9, 1 January 1998 (1998-01-01), pages 43 - 44, XP009139131, ISSN: 0196-4763 * |
MANZ R ET AL: "Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.92.6.1921, vol. 92, no. 6, 14 March 1995 (1995-03-14), pages 1921 - 1925, XP002007404, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
US20110269152A1 (en) | 2011-11-03 |
EP2390661B1 (en) | 2015-06-24 |
US8663985B2 (en) | 2014-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2146974C (en) | Direct selection of cells by secretion product | |
AU2014232225B2 (en) | Protocol for identifying and isolating antigen-specific B cells and producing antibodies to desired antigens | |
EP2725359B1 (en) | Cell separation method using a release system for cell-antibody-substrate conjugates containing a polyethylene glycol spacer unit | |
AU2005252863A1 (en) | Identification of antibody-producing cells | |
WO1994009117A9 (en) | Direct selection of cells by secretion product | |
Thomas et al. | High gradient magnetic separation of cells on the basis of expression levels of cell surface antigens | |
US7166423B1 (en) | Direct selection of cells by secretion product | |
CN110016462A (en) | The method of single antigen-specific b lymphocyte is efficiently separated from spleen cell | |
JP2003508073A (en) | Method for modifying selected cells in a magnetic cell separation column | |
US10196631B2 (en) | Cell separation method using a release system for cell-antibody-substrate conjugates containing a polyethylene glycol spacer unit | |
US8663985B2 (en) | Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell | |
WO2009103753A1 (en) | Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods | |
Horton et al. | A new and rapid method for the selection and cloning of antigen-specific hybridomas with magnetic microspheres | |
EP1347301A1 (en) | Method for ultra-rapid and ultra-sensitive measurement | |
WO2014147873A1 (en) | Antibody that binds specifically with hmgb1 decomposition product, and method and reagent for assaying hmgb1 decomposition product | |
CN111893086B (en) | Fetal nucleated red blood cell capture carrier, extraction device and method | |
US20180217151A1 (en) | Reversible labeling of antigens in biological specimens | |
US9395370B2 (en) | Purification of monoclonal antibodies | |
CN117607441B (en) | Circulating tumor cell TROP-2 immune chromogenic detection reagent | |
US20020155511A1 (en) | Novel antibody compositions for the negative selection of specific rat leukocyte subsets | |
CN117607463B (en) | EGFR (epidermal growth factor receptor) immune chromogenic detection reagent for circulating tumor cells | |
CN117630370B (en) | HER2 positive CTC (CTC) immunochromatography detection reagent | |
CN117607441A (en) | Circulating tumor cell TROP-2 immune chromogenic detection reagent | |
WO2003028625A2 (en) | Methods for screening monoclonal antibodies on heterogeneous antigen substrates | |
US20170248587A1 (en) | Polymeric Dye Specific Binding Members and Methods of Making and Using the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME RS |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120423 |
|
17Q | First examination report despatched |
Effective date: 20120618 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/569 20060101ALI20141211BHEP Ipc: G01N 33/543 20060101ALI20141211BHEP Ipc: G01N 33/50 20060101AFI20141211BHEP Ipc: G01N 33/68 20060101ALI20141211BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150123 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150414 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 733133 Country of ref document: AT Kind code of ref document: T Effective date: 20150715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010025374 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150924 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 733133 Country of ref document: AT Kind code of ref document: T Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150925 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150924 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20150624 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151026 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150624 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151024 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010025374 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20160329 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160502 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160531 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160531 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150624 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602010025374 Country of ref document: DE Ref country code: DE Ref legal event code: R081 Ref document number: 602010025374 Country of ref document: DE Owner name: MILTENYI BIOTEC B.V. & CO. KG, DE Free format text: FORMER OWNER: MILTENYI BIOTEC GMBH, 51429 BERGISCH GLADBACH, DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20200528 AND 20200603 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230526 Year of fee payment: 14 Ref country code: DE Payment date: 20220620 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230524 Year of fee payment: 14 |